Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event
Oramed Pharmaceuticals Inc. (ORMP)
Last oramed pharmaceuticals inc. earnings: 4/6 04:46 pm
Check Earnings Report
US:NASDAQ Investor Relations:
oramed.com/investors
Company Research
Source: PR Newswire
NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, conducted an investor event and conference call yesterday, November 18, 2019, where a panel of investigators and Key Opinion Leaders presented detailed findings from the Company's successful Phase IIb study of ORMD-0801 in the treatment of type 2 diabetes.Panelists presenting the data included: Dr. Joel Neutel, Principal Investigator of the study and Director of Research at Orange County Research Center; Kenneth Homer, the trial's biostatistician; Dr. Ramachandra Naik, Professor of Medicine/Endocrinology at SUNY Upstate Medical University; and Dr. Alexander Fleming, CEO of Kinexum, and former Head of Clinical Review of Endocrine and Metabolic Drugs at the U.S. Food and Drug Administration (FDA). Key highlights from the investor event included the following:Comments by Dr. Naik
Show less
Read more
Impact Snapshot
Event Time:
ORMP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORMP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORMP alerts
High impacting Oramed Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ORMP
News
- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
ORMP
Earnings
- 8/14/24 - Beat
ORMP
Sec Filings
- 12/17/24 - Form 8-K
- 11/8/24 - Form 4
- 11/8/24 - Form 4
- ORMP's page on the SEC website